Heyholder
‹ Activism Filings

JEIL PHARMACEUTICAL CO.,LTD Q3 operating loss of KRW 6.3 billion, turning to a loss; sales of KRW 136.7 billion

JEIL PHARMACEUTICAL CO.,LTD· Periodic Report

AI summary · Not investment advice

Jeil Pharmaceutical sold KRW 136.7 billion in Q3 but lost KRW 6.3 billion from its main business, down from a profit a year earlier.

Operating profit · 3 months

KRW -6.3 billion

Key facts

Revenue (3 months)
KRW 136.7 billion
Net income (3 months)
KRW -9.8 billion
Period
Q3 (cumulative 2026.01.01 ~ 2026.09.30)
Revenue (prior-year 3 months)
KRW 134.8 billion
Revenue (year to date)
KRW 413.6 billion
Operating profit (prior-year 3 months)
KRW 9.8 billion
Operating profit (year to date)
KRW -12.9 billion
Net income (prior-year 3 months)
KRW 15.9 billion
Net income (year to date)
KRW -13.2 billion

Commentary

AI commentary · Not investment advice

What happened

Jeil Pharmaceutical reported its consolidated results for the third quarter of 2026. Sales for the latest 3 months were KRW 136.88 billion. Operating profit (profit from the core business) was a loss of KRW 6.25 billion. Net income (final profit after taxes and other costs) was a loss of KRW 9.77 billion.

In the company's terms

Sales for the latest 3 months were up 1.4% from a year earlier. They were down 6.8% from the previous quarter. Sales for the same 3 months a year earlier were KRW 134.76 billion.

What changes for shareholders

Operating profit a year earlier was a profit of KRW 9.82 billion, so it has turned to a loss. Net income a year earlier was a profit of KRW 15.87 billion, and it has also turned to a loss.

For the year to date (January 1 to September 30), sales were KRW 413.59 billion. Operating profit was a loss of KRW 12.88 billion. Net income was a loss of KRW 13.22 billion.

Comments

No comments yet

Comments from shareholders will appear here.